小肝癌射频消融与手术切除的疗效分析

目的通过对比研究,评价直径小于5 cm的肝细胞性肝癌（简称小肝癌）射频消融与手术切除治疗的临床疗效。方法选择2001年1月-2006年6月间87例临床诊断为小肝癌患者的资料。根据治疗方法分为射频组和手术组。随访时间6-71个月,采用Kap lan-Meier模型进行生存分析,Log-Rank试验被用来估计生存曲线的不同。结果本研究结束后,共有67例患者存活,20例患者死亡。射频组1、2、3年累积生存率分别为91%、76.7%、69.7%,手术组1、2、3年累积生存率分别为90%、82.9%、75.4%,两者生存曲线的差异经Log-Rank检验无统计学意义（χ^2=0.99,P=0.32）。全组共有43例肿瘤复发,射频组25例,手术组18例。两组间的复发构成比有显著性差异（χ^2=6.47,P=0.01）。射频组与手术组1、2、3年的无瘤生存率分别为57.3%、40.3%、35.3%与71.1%、45.7%、、30.9%,两组的无瘤生存率经Log-Rank检验无统计学差异（χ^2=0.06,P=0.80）。结论对于小肝癌而言,射频消融与手术切除有相近的疗效。射频治疗创伤小、可重复性强,在小肝癌的治疗中有重要的临床应用价值。     

消化道类癌的诊断与治疗(附44例报告)

目的探讨消化道类癌的诊断与治疗. 方法回顾性分析我院1990年1月～2005年4月44例消化道类癌的临床资料. 结果本组44例中直肠(包括直肠乙状结肠交界处)类癌29例发生率最高65.9%(29/44),结肠4例9.1%(4/44),阑尾1例2.3%(1/44),小肠2例4.5%(2/44),十二指肠2例4.5%(2/44),胃5例11.4%(5/44),肝1例2.3%(1/44).44例中治疗了39(39/44,88.6%),其中手术切除14例,内镜下粘膜切除术(EMR)20例(5例EMR后病理断端残余癌细胞又追加手术局部切除),内镜下直接钳除5例,5例未治疗.直径≤1 cm 30例占68.2%, 26例全部治愈,15例(50%)行EMR完全切除,其中20例肠镜随访10～84个月,均无复发,预后好;直径1～2 cm 4例占9.1%,手术局部切除,1例1年后肝转移;直径>2 cm 10例占22.7%,均位于直肠外,8例手术,2例未治疗,3例死亡,5例有远处或淋巴结转移,预后差.44例中6例发生远处或淋巴结转移,转移率13.6%. 结论内镜是诊断消化道类癌的首选方法,≤1cm的类癌可在内镜下行EMR切除.     

涉及全椎骨之脊柱肿瘤的外科治疗

本文报告了4例涉及椎体及其后部结构的全椎骨肿瘤的外科治疗,介绍了全椎骨切除术的手术方法及手术注意事项。手术采用后路附件切除,上下椎体Steffee钢板内固定,前路椎体切除自体髂骨植骨融合,初步效果满意。本手术难度大、出血多、危险性高,术中采用控制性低血压,以减少出血。     

神经内镜治疗脑室内病变

目的探讨脑室内病变的神经内镜治疗。方法应用神经内镜对68例脑室内病变进行治疗,其中松果体区肿瘤16例,囊性颅咽管瘤15例,丘脑肿瘤14例,脑室内囊肿16例,侵及室管膜下的胼胝体肿瘤3例,侧脑室脉络丛乳头状瘤2例,侧脑室猪囊尾蚴病1例,侧脑室内分流管脱落1例。结果随访17～69个月,56例有效,12例死于肿瘤扩散。无严重并发症。结论对脑室内病变选择性应用神经内镜治疗安全、有效。     

经尿道电切与气化切割和激光治疗前列腺增生症的疗效比较

目的 :比较经尿道电切前列腺术 (TURP) ,经尿道前列腺气化切除术 (TUVP)及经尿道接触式激光前列腺切除术 (TULP)的治疗效果。方法 :在 30 0 0例前列腺增生症患者中 ,按三种术式各随机抽取 2 0例术前条件具有可比性的患者 ,进行疗效比较。结果 :3种术式患者手术前后前列腺症状评分 (IPSS)、生活质量评分(QOL)、最大尿流率 (MFR)、剩余尿 (PVR)比较均得到显著改善 (P <0 .0 1) ,3组之间相比差异无显著性意义(P >0 .0 5 )。手术时间 :TUVP及TURP组明显短于TULP组 (P <0 .0 1) ,术中失血量及术后置管时间 :TUVP及TULP组明显少于TURP组 (P <0 .0 1)。TURP组术后继发感染、出血、暂时性尿失禁发生率少于TUVP及TULP组。结论 :3种术式治疗效果相同 ;TUVP操作简单、安全 ,对初学者来说尤其适宜 ;TURP仍为治疗BPH的金标准术式     

Pericardial effusion following pulmonary resection

Objective Postoperative pericardial effusion commonly occurs after open heart surgery. However, after general thoracotomy such as pulmonary resection, there have been few reports of pericardial effusion. The purpose of this study is to investigate patients with pericardial effusion following pulmonary resection.Methods: Among 2,385 patients with pulmonary resection for lung neoplasm in our institute, eight patients, whose pericardium had never been opened during the operation, developed pericardial effusion. The clinical characteristics of the eight patients were analyzed.Results: Pericardial effusion after pulmonary resection was divided into two subtypes: pericardial effusion in three patients with left thoracotomy occurring within 30 days postoperatively, and pericardial effusion in the remaining five patients with right thoracotomy occurring more than 30 days postoperatively. Pericardiotomy or pericardiocentesis was performed in three symptomatic patients, and the remaining five asymptomatic patients were treated with diuretics. Pericardial effusion disappeared in three of the five patients about 1–3 months after the conservative treatment, while, in the remaining patients, because pericardial effusion had increased gradually, pericardiocentesis was performed.Conclusion: From our experience, the treatment strategy of drainage for early pericardial effusion and diuretics for late pericardial effusion seems to be appropriate. (Jpn J Thorac Cardiovasc Surg 2006; 54:193-198)     

ת���Ըΰ�116��������Ч����

目的探讨转移性肝癌的手术治疗效果。方法回顾性分析1996～2003年四川大学华西医院对116例转移性肝癌施行手术切除的情况，比较施行同期手术组与非同期手术组的治疗效果。结果全组无手术死亡，1、3、5年生存率分别为74．1％、39．7％、23．3％，其中同期手术组1、3、5年生存率分别为73．3％、41．7％、21．7％。非同期手术组分别为75．0％、37．5％、25．0％，两组1、3、5年生存率比较差异无显著性(P＞0．05)。结论手术切除是转移性肝癌有效的治疗方法。     

肝部分切除术治疗肝内胆管结石

目的：总结肝部分切除治疗左肝内胆管结石的经验。方法：对1995年至2002年7月152例肝内胆管结石病人，13例行肝部分切除进行总结。结果：在10例行肝左外叶切除，3例行肝左叶切除经验的基础上，总结出在基层医院医疗设备不完善的情况下，控制肝脏手术中出血，简化手术，以免导致肝功能的恶化。减少了术后结石残留和复发率。结论：治疗肝内胆管结石的最有效的手段是切除病变肝段。     

Adenocarcinoma of the Ampulla of Vater: T-Stage,Chromosome 17p Allelic Loss,and Extended Pancreaticoduodenectomy are Relevant Prognostic Factors

Objective To evaluate the prognostic significance of different clinico-pathological and molecular factors, and to compare survival after standard and extended pancreaticoduodenectomy (PD) in ampulla of Vater adenocarcinoma (AVAC). Summary Background Data There are discordant data on factors affecting prognosis, and hence therapeutic choices, in AVAC. Patients and Methods Clinical-pathological factors were evaluated in 59 patients, subjected to PD for AVAC; in 42 subjects information on chromosome 17p and 18q allelic losses (LOH) and microsatellite instability (MSI) was also available. The association between survival and type of PD was investigated in the 25 patients operated between 1990 and 2001 (16 standard and nine extended). Results The overall 5- and 10-year tumor-related survival rates were 46% and 33%, respectively. Sixteen patients had T-stages 1–2, 14 T-stage 3, and 29 T-stage 4 cancers. Chromosome 17p and 18q LOH were detected in 23 (55%) and 15 cases (36%), respectively, and in 12 cases (29%) coexisted. Five cases were MSI-positive (12%). At univariate analysis, poor survival was associated with cancer ulceration (P = 0.051), poor differentiation (P = 0.008), T-stage 4 (P < 0.001), nodal metastases (P = 0.004), chromosome 17p (P < 0.001) and 18q LOH (P = 0.002), and absence of MSI (P = 0.009). At multivariate analysis, only T-stage (P = 0.002) and 17p LOH (P = 0.001) were independent predictors of survival. All patients with MSI-positive cancers were long-survivors (>12 yrs), whereas only 30% of MSI-negative cancer patients survived at 5 years. Extended pancreaticoduodenectomy was associated with a 3-year disease-related survival higher than standard resection (83% vs 31%; P = 0.018). Conclusion MSI and chromosome 17p status allow to better define prognosis within ampullary cancers at the same stage. Surgery alone resulted curative in MSI-positive cancer patients, whereas it was inadequate in patients showing allelic losses, who might benefit from adjuvant therapy. In this observational study, extended PD was associated with increased survival compared to standard procedures. Presented at the 2006 Annual Meeting of the American Hepato-Pancreato-Biliary Association, Miami Beach, Florida, March 9–12, 2006     

肝切除技术的研究进展

肝切除技术已成为治疗各种肝脏良性、恶性肿瘤的最主要方法。文中主要从肝脏切除范围的界定、断肝新技术及腹腔镜肝切除技术这三方面的进展进行综述,从而提高对如何更加完善肝预切除方案和肝脏外科微创化肝脏外科领域里两大研究热点的认识。